Recombinant fusion protein TIGIT-Fc and application in resisting transplant rejection thereof

A technology of fusion protein and transplant rejection, which is applied in the field of biomedicine and can solve the problems that patients do not achieve the desired therapeutic effect
CN108558997AActive Publication Date: 2018-09-21FOURTH MILITARY MEDICAL UNIVERSITY
6 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
FOURTH MILITARY MEDICAL UNIVERSITY
Publication Date
2018-09-21

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a recombinant fusion protein TIGIT-Fc and application in resisting transplant rejection thereof. The linear tandem polypeptide is capable of inducing specific T cell response toexert an immunoprotective effect. The amino acid sequence of the recombinant fusion protein TIGIT-Fc is shown in SEQ ID NO: 1. The nucleotide sequence for encoding the recombinant fusion protein TIGIT-Fc is shown in SEQ. ID. NO: 2. The recombinant fusion protein TIGIT-Fc can effectively regulate macrophage polarization by interfering CD226 / TIGIT-CD155 signaling pathways, which is conducive to theinduction of allograft tolerance.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biomedicine, in particular to a recombinant fusion protein TIGIT-Fc and its application in anti-transplant rejection. Background technique

[0002] Organ transplantation is an important and even the only treatment to save the life and improve the quality of life of patients with end-stage organ failure. Since the 1980s, the field of organ transplantation has developed rapidly. Tissues such as kidney, heart, liver, pancreas and islets, parathyroid gland, lung, bone marrow, and cornea are commonly used solid transplant organs. Kidney transplantation in developed countries has become The preferred conventional therapy for benign end-stage renal disease, surgical operation is no longer the main problem restricting the development of organ transplantation.

[0003] Thanks to the advancement of medical technology and the widespread use of broad-spectrum immunosuppressive drugs, graft failure within the first y...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More